Initial trials in patients showed remarkable anti-tumour reactivity in chronic lymphocytic leukaemia (CLL) [14], acute lymphocytic leukaemia (ALL) [15] and non-Hodgkin lymphoma (NHL) [16], using CAR-T cells targeting CD19. Here, CD19 is linked to non-Hodgkin lymphoma.